Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000062849-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Neuroblastoma Screening
Childhood Astrocytomas Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment of Childhood High-Grade Astrocytomas
Childhood low-grade astrocytomas may recur many years after initial treatment. Recurrent disease is usually at the primary tumor site, although multifocal or widely disseminated disease to other intracranial sites and to the spinal leptomeninges has been documented.[1,2] Most children whose low-grade fibrillary astrocytomas recur will harbor low-grade lesions; however, malignant transformation is possible. Surveillance imaging will frequently identify asymptomatic recurrences.At the time of recurrence, a complete evaluation to determine the extent of the relapse is indicated. Biopsy or surgical resection may be necessary for confirmation of relapse because other entities, such as secondary tumor and treatment-related brain necrosis, may be clinically indistinguishable from tumor recurrence. The need for surgical intervention must be individualized on the basis of the initial tumor type, the length of time between initial treatment and the reappearance of the mass lesion, and the
Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - General Information About Neuroblastoma Cancer
Neuroblastoma is a disease in which malignant (cancer) cells form in nerve tissue.Neuroblastoma often begins in the nerve tissue of the adrenal glands. There are two adrenal glands, one on top of each kidney, in the back of the upper abdomen. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the abdomen, chest, spinal cord, or in nerve tissue near the spine in the neck.Anatomy of the female urinary system showing the kidneys, adrenal glands, ureters, bladder, and urethra. Urine is made in the renal tubules and collects in the renal pelvis of each kidney. The urine flows from the kidneys through the ureters to the bladder. The urine is stored in the bladder until it leaves the body through the urethra.Neuroblastoma most often begins during early childhood, usually in children younger than 5 years of age.See the PDQ summary on Neuroblastoma Treatment for more
Spinocerebellar Ataxia with Axonal Neuropathy
SCAN1 is a neurodegenerative disorder that is inherited in an autosomal recessive pattern. Spinocerebellar ataxia with axonal neuropathy (SCAN1) is characterized by late childhood-onset of a slowly progressive cerebellar ataxia,followed by areflexia and signs of peripheral neuropathy. Gaze nystagmus and cerebellar dysarthria usually develop after the onset of ataxic gait. As the disease ...
Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (10 / 24 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Adult Brain Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062900-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Adult Brain Tumors Treatment
Neuroblastoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment of Stage 4S Neuroblastoma
Most cases of stage 4S neuroblastoma do not require therapy. However, if bulk disease is causing organ compromise and risk of death, low-dose to moderate-dose chemotherapy and/or radiation therapy is used. Eight percent to 10% of these patients will have MYCN amplification and are treated with high-risk protocols. (Refer to the Treatment of High-Risk Neuroblastoma section of this summary for more information about the treatment of stage 4S high-risk neuroblastoma.)Table 9. Children's Oncology Group (COG) Neuroblastoma Stage 4S Group Assignment Schema Used for COG-P9641 and COG-A3961 StudiesaINSS StageAgeMYCNStatusINPC ClassificationDNA PloidybRisk GroupINPC = International Neuroblastoma Pathologic Classification; INSS = International Neuroblastoma Staging System.a The COG-P9641 and COG-A3961 trials established the current standard of care for neuroblastoma patients in terms of risk group assignment and treatment strategies.b DNA Ploidy: DNA Index (DI) > 1 is favorable, = 1 is
Neuroblastoma Screening (PDQ®): Screening - Health Professional Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Childhood Ependymoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Childhood Ependymoma
The PDQ childhood brain tumor treatment summaries are organized primarily according to the World Health Organization (WHO) classification of nervous system tumors.[1,2] For a full description of the classification of nervous system tumors and a link to the corresponding treatment summary for each type of brain tumor, refer to the PDQ summary on Childhood Brain and Spinal Cord Tumors Treatment Overview.Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2010, childhood cancer mortality decreased by more than 50%. Childhood and adolescent cancer survivors require close follow-up because cancer therapy side effects may persist or develop months or years after treatment. (Refer to the PDQ summary Late Effects of Treatment for Childhood Cancer for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.)Primary brain tumors are a diverse group of diseases that